

Supplementary Documents [IFRS]

Financial results for the first three months of the fiscal year 2025 (FY2025)

Astellas Pharma Inc.

- Q1 YTD/FY2025 Financial Results
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[Three months ended June 30, 2025]

1. Consolidated Results (Full Basis)

Unit: B¥					Change from Forecasts FY24		
	FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)	FY24 Full Year	FY25 Full Year	Change (%)
Revenue	473.1	505.8	32.7	6.9%	1,912.3	1,930.0	0.9%
Cost of sales	91.1	94.8	3.7	4.1%	349.2	373.0	6.8%
Gross profit	382.0	411.0	29.0	7.6%	1,563.1	1,557.0	-0.4%
SG&A expenses	206.9	197.0	-9.9	-4.8%	843.0	805.0	-4.5%
XTANDI co-promotion fee in the United States	61.6	62.9	1.3	2.1%	252.6	229.0	-9.3%
SG&A excl. the above	145.3	134.1	-11.2	-7.7%	590.5	576.0	-2.5%
Ratio to Revenue	30.7%	26.5%			30.9%	29.8%	
R&D expenses	86.8	71.7	-15.1	-17.4%	327.7	342.0	4.4%
Ratio to Revenue	18.4%	14.2%			17.1%	17.7%	
Amortisation of intangible assets	35.0	32.8	-2.2	-6.4%	136.8		
Gain on divestiture of intangible assets	0.9	3.7	2.8	306.9%	1.0		
Share of profit (loss) of investments accounted for using equity method	1.9	-1.6	-3.5	-	-0.3		
Other income	4.9	4.4	-0.5	-10.8%	20.3		
Net foreign exchange gains	1.9	-	-1.9	-	-		
Fair value remeasurements on contingent consideration	2.0	4.0	2.0	97.7%	16.7		
Other expenses	10.4	21.3	11.0	105.5%	235.8		
Impairment losses for intangible assets	0.6	13.6	12.9	-	187.6		
Restructuring costs	2.6	2.8	0.2	8.7%	15.5		
Net foreign exchange losses	-	2.3	2.3	-	18.6		
Fair value remeasurements on contingent consideration	5.7	0.7	-5.0	-87.0%	-		
Operating profit	50.7	94.6	44.0	86.8%	41.0	160.0	289.9%
Ratio to Revenue	10.7%	18.7%			2.1%	8.3%	
Finance income	4.3	1.7	-2.7	-61.5%	7.9		
Finance expenses	4.5	5.9	1.4	31.2%	17.7		
Profit before tax	50.5	90.4	39.9	79.1%	31.2	150.0	380.2%
Income tax expense	12.9	22.0	9.1	70.6%	-19.5		
Profit	37.6	68.4	30.8	82.0%	50.7	130.0	156.2%
Comprehensive income	149.5	34.9	-114.6	-76.7%	48.9		

2. Consolidated Results (Core Basis)

Unit: B¥

	FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)
Revenue	473.1	505.8	32.7	6.9%
Cost of sales	91.1	94.8	3.7	4.1%
Gross profit	382.0	411.0	29.0	7.6%
SG&A expenses	206.9	197.0	-9.9	-4.8%
XTANDI co-promotion fee in the United States	61.6	62.9	1.3	2.1%
SG&A excl. the above	145.3	134.1	-11.2	-7.7%
Ratio to Revenue	30.7%	26.5%		
R&D expenses	86.8	71.7	-15.1	-17.4%
Ratio to Revenue	18.4%	14.2%		
Operating profit	88.3	142.3	54.0	61.1%
Ratio to Revenue	18.7%	28.1%		
Finance income	4.3	1.7	-2.7	-61.5%
Finance expenses	4.5	5.9	1.4	31.2%
Profit before tax	88.1	138.0	49.9	56.6%
Income tax expense	21.0	33.3	12.3	58.8%
Profit	67.2	104.7	37.6	56.0%

Change from
FY24

Forecasts	FY25 Full Year	Change (%)
FY24 Full Year	1,912.3	0.9%
	349.2	6.8%
	1,563.1	-0.4%
	843.0	-4.5%
	252.6	-9.3%
	590.5	-2.5%
	30.9%	
	327.7	4.4%
	17.1%	
	392.4	4.5%
	20.5%	
	7.9	
	17.7	
	382.6	
	87.0	
	295.7	2.8%

3. Exchange Rate

Unit: yen

	FY24 APR. - JUN.Ave.	FY25 APR. - JUN.Ave.	FY24 End	FY25 Q1 End
USD/Yen	156	145	150	144
EUR/Yen	168	164	162	170

Forecasts

FY24 Full Year	FY25 Full Year
152	140
164	160

* Fx impacts: Revenue -26.1 billion yen and Core operating profit -7.1 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY24 APR. - JUN.			FY25 APR. - JUN.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	473.1	-	473.1	505.8	-	505.8
Cost of sales	91.1	-	91.1	94.8	-	94.8
Gross profit	382.0	-	382.0	411.0	-	411.0
SG&A expenses	206.9	-	206.9	197.0	-	197.0
R&D expenses	86.8	-	86.8	71.7	-	71.7
Amortisation of intangible assets *	35.0	-35.0	-	32.8	-32.8	-
Gain on divestiture of intangible assets *	0.9	-0.9	-	3.7	-3.7	-
Share of profit (loss) of investments accounted for using equity method *	1.9	-1.9	-	-1.6	1.6	-
Other income *	4.9	-4.9	-	4.4	-4.4	-
Other expenses *	10.4	-10.4	-	21.3	-21.3	-
Operating profit	50.7	37.6	88.3	94.6	47.6	142.3
Finance income	4.3	-	4.3	1.7	-	1.7
Finance expenses	4.5	-	4.5	5.9	-	5.9
Profit before tax	50.5	37.6	88.1	90.4	47.6	138.0
Income tax expense	12.9	8.1	21.0	22.0	11.3	33.3
Profit	37.6	29.5	67.2	68.4	36.3	104.7

* 'Amortisation of intangible assets', 'Gain on divestiture of intangible assets', 'Share of profit (loss) of investments accounted for using equity method', 'Other income' and 'Other expenses' are excluded from Core basis results.
 "Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

		Unit: B¥				Change from FY24		
		FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)	FY24 Full Year	FY25 Full Year	Change (%)
Revenue		473.1	505.8	32.7	6.9%	1,912.3	1,930.0	0.9%
	Japan	66.7	68.9	2.3	3.4%	267.0	285.0	6.7%
	Ratio to Revenue	14.1%	13.6%			14.0%	14.8%	
	United States	212.1	224.7	12.6	6.0%	866.4	856.0	-1.2%
	Ratio to Revenue	44.8%	44.4%			45.3%	44.4%	
	Established Markets	121.0	128.8	7.7	6.4%	485.4	492.0	1.4%
	Ratio to Revenue	25.6%	25.5%			25.4%	25.5%	
	China	18.7	29.4	10.8	57.8%	78.3	89.0	13.7%
	Ratio to Revenue	3.9%	5.8%			4.1%	4.6%	
	International Markets	52.0	53.2	1.2	2.3%	203.5	202.0	-0.7%
	Ratio to Revenue	11.0%	10.5%			10.6%	10.5%	

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

6. Investment in Property, Plant and Equipment

Depreciation/Amortisation

		Unit: B¥				Change from FY24		
		FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)	FY24 Full Year	FY25 Full Year	Change (%)
Investment in Property, Plant and Equipment		13.5	4.8	-8.6	-64.1%	47.8	55.0	15.1%
Depreciation (PP&E)		10.9	11.1	0.2	2.2%	44.9	45.0	0.2%
Amortisation of Intangible Assets (incl. software, etc.)		39.4	36.7	-2.7	-6.9%	154.2	155.0	0.5%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

7. Sales of major products

1) Global

		Unit: B¥				Forecasts		
		FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)	FY24 Full Year	FY25 Full Year	Change (%)
PADCEV		38.4	55.5	17.1	44.6%	164.1	200.0	21.9%
	Japan	2.5	5.1	2.6	102.3%	12.6	27.0	114.3%
	United States	27.2	31.7	4.5	16.7%	109.1	111.0	1.7%
	Established Markets	7.5	9.5	2.0	26.1%	32.7	40.0	22.3%
	China	0.1	7.4	7.3	-	3.9	12.0	207.7%
	International Markets	1.1	1.8	0.7	62.6%	5.7	9.0	57.9%
IZERVAY		12.7	15.9	3.2	25.2%	58.3	105.0	80.1%
	United States	12.7	15.9	3.2	25.2%	58.3	105.0	80.1%
VEOZAH		6.6	9.6	3.0	45.6%	33.8	50.0	47.9%
	United States	6.1	8.6	2.4	39.7%	30.8	39.0	26.6%
	Established Markets	0.4	0.9	0.5	107.2%	2.7	8.0	196.3%
	International Markets	0.0	0.1	0.1	861.7%	0.3	1.0	233.3%
VYLOY		0.3	14.0	13.7	-	12.2	40.0	227.9%
	Japan	0.3	3.1	2.8	791.2%	5.2	14.0	169.2%
	United States	-	5.9	5.9	-	4.9	16.0	226.5%
	Established Markets	-	1.7	1.7	-	2.2	5.0	127.3%
	China	-	3.3	3.3	-	-	4.0	-
	International Markets	-	0.1	0.1	-	-	1.0	-
XOSPATA		17.3	17.0	-0.3	-1.9%	68.0	75.0	10.3%
	Japan	1.3	1.3	0.0	3.8%	4.7	6.0	27.7%
	United States	8.9	7.4	-1.6	-17.8%	35.0	36.0	2.9%
	Established Markets	4.6	5.6	1.0	20.8%	18.9	19.0	0.5%
	China	1.4	1.0	-0.4	-26.6%	3.9	5.0	28.2%
	International Markets	1.1	1.7	0.6	57.0%	5.5	7.0	27.3%
XTANDI		224.2	233.0	8.7	3.9%	912.3	868.0	-4.9%
	Japan	14.9	15.9	1.1	7.1%	57.9	60.0	3.6%
	United States	119.8	122.6	2.8	2.4%	491.7	446.0	-9.3%
	Established Markets	65.7	69.5	3.8	5.7%	262.1	261.0	-0.4%
	China	3.0	4.8	1.8	58.3%	16.3	18.0	10.4%
	International Markets	20.9	20.2	-0.7	-3.2%	84.3	82.0	-2.7%
BETANIS/MYRBETRIQ/BETMIGA		46.1	43.0	-3.1	-6.8%	170.0	134.0	-21.2%
PROGRAF		53.9	51.2	-2.7	-4.9%	201.0	186.0	-7.5%

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Pfizer

- VEOZAH: Approved as "VEOZA" in ex-US

2) Revenue by region

(1) Japan

		Unit: B¥				Change from FY24		
		FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)	FY24 Full Year	FY25 Full Year	Change (%)
Revenue		66.7	68.9	2.3	3.4%	267.0	285.0	6.7%
	PADCEV	2.5	5.1	2.6	102.3%	12.6	27.0	114.3%
	VYLOY	0.3	3.1	2.8	791.2%	5.2	14.0	169.2%
	XOSPATA	1.3	1.3	0.0	3.8%	4.7	6.0	27.7%
	XTANDI	14.9	15.9	1.1	7.1%	57.9	60.0	3.6%
	BETANIS	6.6	5.7	-0.9	-14.3%	24.6	24.0	-2.4%
	PROGRAF (Including GRACEPTOR)	6.4	4.6	-1.7	-27.4%	21.2	18.0	-15.1%
	SUGLAT [Family]	7.0	6.3	-0.7	-10.2%	26.4	24.0	-9.1%
	BLINCYTO	3.2	3.5	0.3	8.2%	13.4		
	EVENITY	13.8	16.5	2.8	20.1%	57.9		

(2) United States

		Unit: M\$				Change from FY24		
		FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)	FY24 Full Year	FY25 Full Year	Change (%)
Revenue		1,360	1,555	195	14.3%	5,683	6,120	7.5%
	PADCEV	174	219	45	25.9%	716	790	10.3%
	IZERVAY	82	110	29	35.0%	382	750	96.3%
	VEOZAH	39	59	20	50.7%	202	280	38.6%
	VYLOY	-	41	41	-	32	120	275.0%
	XOSPATA	57	51	-6	-11.3%	230	260	13.0%
	XTANDI	768	848	80	10.4%	3,225	3,180	-1.4%
	MYRBETRIQ	120	107	-13	-11.1%	410	210	-48.8%
	CRESEMBA	70	80	10	14.5%	310	350	12.9%

(3) Established Markets

		Unit: M€				Change from FY24		
		FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)	FY24 Full Year	FY25 Full Year	Change (%)
Revenue		721	786	64	8.9%	2,967	3,070	3.8%
	PADCEV	45	58	13	29.1%	200	250	25.0%
	VEOZA	3	5	3	112.1%	17	50	194.1%
	VYLOY	-	10	10	-	13	30	130.8%
	XOSPATA	27	34	7	23.7%	115	120	4.3%
	XTANDI	391	424	32	8.3%	1,602	1,630	1.7%
	BETMIGA	92	102	10	10.4%	382	390	2.1%
	PROGRAF	115	113	-1	-1.1%	459	440	-4.1%

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

	FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)
Revenue	18.7	29.4	10.8	57.8%
PADCEV	0.1	7.4	7.3	-
VYLOY	-	3.3	3.3	-
XOSPATA	1.4	1.0	-0.4	-26.6%
XTANDI	3.0	4.8	1.8	58.3%
PROGRAF	11.2	10.4	-0.8	-7.5%

FY24 Full Year
78.3
3.9
-
3.9
16.3
43.0

Forecasts		Change from FY24
FY25 Full Year	Change (%)	
89.0	13.7%	
12.0	207.7%	
4.0	-	
5.0	28.2%	
18.0	10.4%	
40.0	-7.0%	

- China: China, Hong Kong

(5) International Markets

Unit: B¥

	FY24 APR. - JUN.	FY25 APR. - JUN.	Change	Change (%)
Revenue	52.0	53.2	1.2	2.3%
PADCEV	1.1	1.8	0.7	62.6%
VEOZA	0.0	0.1	0.1	861.7%
VYLOY	-	0.1	0.1	-
XOSPATA	1.1	1.7	0.6	57.0%
XTANDI	20.9	20.2	-0.7	-3.2%
BETMIGA	4.9	5.0	0.1	1.3%
PROGRAF	14.4	14.9	0.5	3.7%

FY24 Full Year
203.5
5.7
0.3
-
5.5
84.3
18.8
51.4

Forecasts		Change from FY24
FY25 Full Year	Change (%)	
202.0	-0.7%	
9.0	57.9%	
1.0	233.3%	
1.0	-	
7.0	27.3%	
82.0	-2.7%	
17.0	-9.6%	
48.0	-6.6%	

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

8. Consolidated statements of financial position

Unit: B¥

	FY24 End	FY25 Q1 End	Change
Assets	3,339.5	3,335.8	-3.7
Non-current assets	2,138.2	2,042.5	-95.7
Property, plant and equipment	328.9	323.4	-5.6
Goodwill	415.2	402.5	-12.7
Intangible assets	1,123.7	1,036.7	-87.0
Trade and other receivables	18.5	18.4	-0.0
Investments accounted for using equity method	19.0	16.8	-2.2
Deferred tax assets	98.1	111.5	13.4
Other financial assets	106.2	106.3	0.1
Other non-current assets	28.6	27.0	-1.6
Current assets	1,201.3	1,293.3	92.0
Inventories	297.3	305.7	8.4
Trade and other receivables	632.5	668.9	36.3
Income tax receivable	13.7	12.2	-1.5
Other financial assets	29.9	37.8	7.9
Other current assets	39.2	53.0	13.8
Cash and cash equivalents	188.4	215.4	27.0
Assets held for sale	0.4	0.4	0.0

Unit: B¥

	FY24 End	FY25 Q1 End	Change
Equity and Liabilities	3,339.5	3,335.8	-3.7
Equity	1,513.3	1,481.8	-31.5
Equity attributable to owners of the parent	1,513.3	1,481.8	-31.5
Share capital	103.0	103.0	-
Capital surplus	185.3	183.3	-2.0
Treasury shares	-37.5	-35.7	1.8
Retained earnings	740.9	742.2	1.3
Other components of equity	521.6	488.9	-32.6
Liabilities	1,826.3	1,854.0	27.8
Non-current liabilities	764.7	746.1	-18.6
Bonds and borrowings	564.9	558.1	-6.8
Income tax payable	3.2	4.5	1.2
Deferred tax liabilities	5.4	5.6	0.2
Retirement benefit liabilities	22.7	22.4	-0.3
Provisions	8.1	10.5	2.4
Other financial liabilities	106.8	100.3	-6.4
Other non-current liabilities	53.6	44.7	-8.8
Current liabilities	1,061.6	1,107.9	46.3
Bonds and borrowings	266.5	331.4	64.9
Trade and other payables	187.8	165.9	-21.9
Income tax payable	34.5	34.9	0.4
Provisions	17.3	16.6	-0.7
Other financial liabilities	20.1	23.4	3.3
Other current liabilities	535.3	535.7	0.4

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Jul 2025

Underlined items indicate changes from the previous announcement in Apr 2025.

Strategic Brands (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III	In-house [Co-development with Pfizer]	
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-II		
			Acute myeloid leukemia in pediatric patients	P-III		
zolbetuximab IMAB362 (VYLOY)	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma (combo with pembrolizumab and chemotherapy)	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
fezolinetant ESN364 (VEOZAH***)	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China P-III Japan P-III	In-house (Ogeda)	
			Vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy	P-III		

Strategic Brands (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
avacincaptad pegol (IZERVAY)	Pegylated RNA aptamer	Complement C5 inhibitor	Geographic atrophy secondary to age-related macular degeneration	Japan Filed (Feb 2025)		
			Stargardt disease	P-II	In-house (Iveric Bio)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** Approved as "VEOZA" in ex-US.

Updates from the previous announcement (Apr 2025):

enfortumab vedotin: Discontinued Phase 1 program for non-muscle-invasive bladder cancer. Discontinued Phase 2 program for other solid tumors.

Programs with Focus Area approach

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Immunology	ASP1570	Small molecule	DGK ζ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
	ASP1002	Antibody	Anti-Claudin 4 and anti-CD137 bispecific antibody	Cancer	P-I	In-house	
Targeted Protein Degradation	ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
	ASP4396	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
Genetic regulation	resamirigene bilparvovec AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	zocaglusagene nuzaparvovec AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-II	In-house (Audentes Therapeutics)	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelial cells	Geographic atrophy secondary to age-related macular degeneration	P-I	In-house (Ocata Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Apr 2025):

ASP1012: Discontinued Phase 1 program for cancer.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron YM178	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients (aged 6 months to less than 3 years)	Europe P-III	In-house	
roxadustat ASP1517/FG-4592	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
abiraterone decanoate ASP5541/PRL-02	Small molecule	CYP17 lyase inhibitor	Prostate cancer	P-I	In-house (Propella Therapeutics)	
ASP546C/XNW27011	Antibody-drug conjugate (ADC)	<u>Claudin 18.2-targeted ADC</u>	<u>Cancer</u>	<u>P-I</u>	<u>Evopoint Biosciences</u>	<u>Astellas has worldwide rights, excluding China's mainland, Hong Kong, Macau, and Taiwan.</u>
ASP5502	Small molecule	STING inhibitor	Primary Sjogren's syndrome	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Apr 2025):

ASP546C/XNW27011: Added a program.

Rx+ Program

As of Jul 2025

Category	Program	Concept	Status*	Partner	Remarks
Digital health	BlueStar	Digital therapeutic for the management of diabetes	Pivotal study (Japan)	Welldoc Roche Diabetes Care Japan	
Drug-device combination	pudexacianinium chloride ASP5354	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	
Implantable medical device	Implantable bladder device	Implantable device for underactive bladder	FDA approved to enter into early feasibility study	(iota Biosciences)	

* The list shows the most advanced stage if the stages are different depending on the region.